Trial · NCT02097277
Adverse events85
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 85
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Injection Site Bruising | General disorders | Treatment A: Placebo | 5 | 24 | |
| other | Injection Site Bruising | General disorders | Treatment B: BMS-986036 (1 mg Daily) | 6 | 24 | |
| other | Injection Site Bruising | General disorders | Treatment C: BMS-986036 (5 mg Daily) | 4 | 24 | |
| other | Injection Site Bruising | General disorders | Treatment D: BMS-986036 (20 mg Daily) | 1 | 24 | |
| other | Injection Site Bruising | General disorders | Treatment E: BMS-986036 (20 mg Weekly) | 3 | 24 | |
| other | Injection Site Erythema | General disorders | Treatment A: Placebo | 1 | 24 | |
| other | Injection Site Erythema | General disorders | Treatment B: BMS-986036 (1 mg Daily) | 1 | 24 | |
| other | Injection Site Erythema | General disorders | Treatment C: BMS-986036 (5 mg Daily) | 0 | 24 | |
| other | Injection Site Erythema | General disorders | Treatment D: BMS-986036 (20 mg Daily) | 2 | 24 | |
| other | Injection Site Erythema | General disorders | Treatment E: BMS-986036 (20 mg Weekly) | 1 | 24 | |
| other | Fatigue | General disorders | Treatment A: Placebo | 0 | 24 | |
| other | Fatigue | General disorders | Treatment B: BMS-986036 (1 mg Daily) | 1 | 24 | |
| other | Fatigue | General disorders | Treatment C: BMS-986036 (5 mg Daily) | 1 | 24 | |
| other | Fatigue | General disorders | Treatment D: BMS-986036 (20 mg Daily) | 0 | 24 | |
| other | Fatigue | General disorders | Treatment E: BMS-986036 (20 mg Weekly) | 2 | 24 | |
| other | Hunger | General disorders | Treatment A: Placebo | 0 | 24 | |
| other | Hunger | General disorders | Treatment B: BMS-986036 (1 mg Daily) | 0 | 24 | |
| other | Hunger | General disorders | Treatment C: BMS-986036 (5 mg Daily) | 2 | 24 | |
| other | Hunger | General disorders | Treatment D: BMS-986036 (20 mg Daily) | 2 | 24 | |
| other | Hunger | General disorders | Treatment E: BMS-986036 (20 mg Weekly) | 0 | 24 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02097277/events